[go: up one dir, main page]

WO1996013259A3 - Method and compositions for inhibiting protein kinases - Google Patents

Method and compositions for inhibiting protein kinases Download PDF

Info

Publication number
WO1996013259A3
WO1996013259A3 PCT/US1995/013882 US9513882W WO9613259A3 WO 1996013259 A3 WO1996013259 A3 WO 1996013259A3 US 9513882 W US9513882 W US 9513882W WO 9613259 A3 WO9613259 A3 WO 9613259A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
independently represents
protein kinases
inhibiting protein
double bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/013882
Other languages
French (fr)
Other versions
WO1996013259A2 (en
Inventor
Neill A Giese
Nathalie Lokker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COR Therapeutics Inc
Original Assignee
COR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by COR Therapeutics Inc filed Critical COR Therapeutics Inc
Priority to AU42789/96A priority Critical patent/AU706621B2/en
Priority to DE69524628T priority patent/DE69524628T2/en
Priority to JP8514745A priority patent/JPH10508024A/en
Priority to AT95941340T priority patent/ATE210439T1/en
Priority to EP95941340A priority patent/EP0788356B9/en
Priority to DK95941340T priority patent/DK0788356T3/en
Priority to KR1019970702786A priority patent/KR970706812A/en
Publication of WO1996013259A2 publication Critical patent/WO1996013259A2/en
Publication of WO1996013259A3 publication Critical patent/WO1996013259A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)

Abstract

A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a molecule of formula (I) wherein R1 is H, lower alkyl, or lower alkanoyl; R2 is H, lower alkyl, or lower alkanoyl; R3 and R4 together represent a cis double bond or -O- or each of R3 and R4 independently represents H or OR; R5 is =O, =S, or -H, -OR; R6 and R7 together represent a double bond or -O- or each of R6 and R7 independently represents H or OR; R8 and R9 together represent a double bond or -O- or each of R8 and R9 independently represents H or OR; and each R independently represents H, lower alkyl, or lower alkanoyl.
PCT/US1995/013882 1994-10-28 1995-10-26 Method and compositions for inhibiting protein kinases Ceased WO1996013259A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU42789/96A AU706621B2 (en) 1994-10-28 1995-10-26 Method and compositions for inhibiting protein kinases
DE69524628T DE69524628T2 (en) 1994-10-28 1995-10-26 METHOD AND MEANS FOR INHIBITING PROTEIN KINASES
JP8514745A JPH10508024A (en) 1994-10-28 1995-10-26 Methods and compositions for inhibiting protein kinases
AT95941340T ATE210439T1 (en) 1994-10-28 1995-10-26 METHOD AND MEANS FOR INHIBITING PROTEIN KINASES
EP95941340A EP0788356B9 (en) 1994-10-28 1995-10-26 Method and compositions for inhibiting protein kinases
DK95941340T DK0788356T3 (en) 1994-10-28 1995-10-26 Methods and Preparations for Inhibition of Protein Kinases
KR1019970702786A KR970706812A (en) 1994-10-28 1995-10-26 METHOD AND COMPOSITIONS FOR INHIBITING PROTEIN KINASES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/332,597 1994-10-28
US08/332,597 US5795910A (en) 1994-10-28 1994-10-28 Method and compositions for inhibiting protein kinases

Publications (2)

Publication Number Publication Date
WO1996013259A2 WO1996013259A2 (en) 1996-05-09
WO1996013259A3 true WO1996013259A3 (en) 1996-08-01

Family

ID=23298937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/013882 Ceased WO1996013259A2 (en) 1994-10-28 1995-10-26 Method and compositions for inhibiting protein kinases

Country Status (14)

Country Link
US (3) US5795910A (en)
EP (1) EP0788356B9 (en)
JP (1) JPH10508024A (en)
KR (1) KR970706812A (en)
CN (1) CN1165481A (en)
AT (1) ATE210439T1 (en)
AU (1) AU706621B2 (en)
CA (1) CA2203757A1 (en)
DE (1) DE69524628T2 (en)
DK (1) DK0788356T3 (en)
ES (1) ES2170172T3 (en)
PT (1) PT788356E (en)
TW (1) TW467743B (en)
WO (1) WO1996013259A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699843B2 (en) * 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
WO1998005999A1 (en) * 1996-08-06 1998-02-12 Seiko Epson Corporation Liquid crystal display and electronics equipment using the same
WO2000009113A1 (en) * 1998-08-17 2000-02-24 Trout William E Use of zeranol to modulate reproductive cycles
US20030219427A1 (en) * 1998-08-18 2003-11-27 Allen Hamish J. TPL-2/COT kinase and methods of use
IL143488A0 (en) * 1998-12-07 2002-04-21 Ecosmart Technologies Inc Cancer treatment composition and method using natural plant essential oils
EP1140069A1 (en) 1998-12-24 2001-10-10 Novation Pharmaceuticals Inc. COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR
SK2142002A3 (en) * 1999-08-13 2002-07-02 Scripps Research Inst Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US7087608B2 (en) * 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
JP2004292314A (en) * 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd Proliferation inhibitor of keratinocyte
US6565864B2 (en) 2000-12-28 2003-05-20 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Skin care product containing retinoids and phytoestrogens in a dual compartment package
CN1273608C (en) * 2001-02-09 2006-09-06 荷兰联合利华有限公司 Process for producing one or more statins by fermentation
WO2003041643A2 (en) * 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
FR2835252B1 (en) * 2002-01-25 2005-08-05 Seppic Sa USE OF A PROTEIN KINASE A INACTIFYING COMPOUND IN A COMPOSITION CONTAINING A COSMETICALLY ACCEPTABLE MEDIUM FOR LAMINATING THE SKIN
US7915306B2 (en) * 2002-03-08 2011-03-29 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
CN1653059A (en) * 2002-03-08 2005-08-10 卫材株式会社 Macrocyclic compounds used as pharmaceuticals
CA2482940A1 (en) * 2002-04-17 2003-10-23 Taisho Pharmaceuticals Co., Ltd. Hair growth tonic
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO2004087104A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US20060079494A1 (en) * 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
ES2651019T3 (en) 2006-08-11 2018-01-23 Universite De Strasbourg Useful macrocyclic compounds as kinase and HSP90 inhibitors
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
JP5484327B2 (en) 2007-07-25 2014-05-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Multi-kinase inhibitors for use in the treatment of cancer
WO2009058908A2 (en) 2007-10-29 2009-05-07 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
CA2708143C (en) 2007-12-07 2016-10-11 Francis G. Fang Intermediates in the synthesis of zearalenone macrolide analogs
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401613A2 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CN101928700B (en) * 2009-07-28 2012-05-02 北京恒宇视野生物科技有限公司 Protein kinase PFTK1 monoclonal antibody and preparation method thereof
US9120768B2 (en) 2010-08-20 2015-09-01 The Hospital For Sick Children Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2016196256A2 (en) 2015-06-04 2016-12-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251813A2 (en) * 1986-07-03 1988-01-07 IMCERA Group Inc. Immunostimulating agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196019A (en) * 1964-04-06 1965-07-20 Purdue Research Foundation Anabolic and estrogenic compound and process of making
JPS6239558A (en) * 1985-08-13 1987-02-20 Kanegafuchi Chem Ind Co Ltd Alpha-cyanoacrylamide derivative
JPS6239523A (en) * 1985-08-14 1987-02-20 Kanegafuchi Chem Ind Co Ltd Antienzyme
JPS6242923A (en) * 1985-08-19 1987-02-24 Kanegafuchi Chem Ind Co Ltd Enzyme inhibitor
JPS6242925A (en) * 1985-08-20 1987-02-24 Kanegafuchi Chem Ind Co Ltd Enzyme inhibitor
GB9225396D0 (en) * 1992-12-04 1993-01-27 Sandoz Ltd Improvements in or relating to organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251813A2 (en) * 1986-07-03 1988-01-07 IMCERA Group Inc. Immunostimulating agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D.T. ZAVA ET AL.: "Effects of plant and fungal estrogens on E-sensitive human breast cancer cells.", PROC. ANNU. MEET. AM. ASSOC. CANCER RES., vol. 35, 1994, pages 88, XP002001543 *
J. CHUNG ET AL.: "Rapamycin-FKBP specifically blocks growth-dependent activation of and signalling by the 70kd S6 protein kinases.", CELL, vol. 69, no. 7, 1992, pages 1227 - 1236, XP000567055 *
R. THUST ET AL.: "Genotoxicity of Fusarium mycotoxins (nivalenol, fusarenon-x, t-2 toxin and zearalenone) in chinese hamster V79-E cells in vitro.", ARCH. GESCHWULSTFORSCH., vol. 53, no. 1, 1983, pages 9 - 15, XP000568651 *
R.G. ARORA ET AL.: "Inhibition of ochratoxin A teratogenesis by zearalenone and diethylstilbestrol.", FOOD CHEM. TOXICOL., vol. 21, no. 6, 1983, pages 779 - 783, XP000568648 *

Also Published As

Publication number Publication date
TW467743B (en) 2001-12-11
EP0788356B9 (en) 2002-10-02
AU4278996A (en) 1996-05-23
KR970706812A (en) 1997-12-01
DE69524628D1 (en) 2002-01-24
ES2170172T3 (en) 2002-08-01
AU706621B2 (en) 1999-06-17
PT788356E (en) 2002-06-28
JPH10508024A (en) 1998-08-04
CA2203757A1 (en) 1996-05-09
US5728726A (en) 1998-03-17
CN1165481A (en) 1997-11-19
DK0788356T3 (en) 2002-03-18
EP0788356A2 (en) 1997-08-13
US5674892A (en) 1997-10-07
DE69524628T2 (en) 2002-08-08
US5795910A (en) 1998-08-18
ATE210439T1 (en) 2001-12-15
MX9703113A (en) 1998-06-30
WO1996013259A2 (en) 1996-05-09
EP0788356B1 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
WO1996013259A3 (en) Method and compositions for inhibiting protein kinases
AU3367995A (en) New multimerizing agents
AU1980997A (en) Synthetic Multimerizing Agents
BG103485A (en) Ketobanzamides as calpain inhibitors
MY114792A (en) Farnesyl transferase inhibitors,their preparation and pharmaceutical compositions comprising them
EP0945452A4 (en) Sugar compounds, gelling agents, gelling agent compositions, processes for the preparation of them, and gel compositions
CA2161542A1 (en) Novel 5-Pyrrolyl-2-Pyridylmethylsulfinyl Benzimidazole Derivatives
NO984470L (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
CA2252039A1 (en) Isatin derivatives as acetylcholinesterase inhibitors and analgesics
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
CA2244777A1 (en) 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
EG20726A (en) Process for preparing of galanthamine derivatives as acetylchol inc-sterase inhibitors
CA2264569A1 (en) Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
PL326554A1 (en) Derivatives of amine and thiourea and inhibitors of nitrogen oxide synthase
UA66748C2 (en) Phenyl substituted 4-azasteroids fluroderivatives, methods for the preparation thereof (variants) and pharmaceutical composition based thereon
AU2717100A (en) Prenyl transferase inhibitors
GR3029590T3 (en) Crystalline, polymorphic form of (s,s,s)-n-(1- 2-carboxy-3-(n?2 -mesyllysylamino)propyl]-1-cyclopentylcarbonyl)tyrosine
WO1999048851A3 (en) Processes for preparing intermediates
CA2154668A1 (en) Condensed heterocyclic glutamic acid derivatives as antiproliferative agents
CA2276203A1 (en) N-(pyridinylamino)isoindolines and related compounds
CA1262904C (en)
WO1998017666A3 (en) Process for the preparation of tetrahydro-5-oxo-pyrrolizine derivatives
AU4734397A (en) Preparation of 3-fluoro oxindole derivatives
CA2294351A1 (en) Compounds useful for inhibition of farnesyl protein transferase
CA2298639A1 (en) Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95195945.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2203757

Country of ref document: CA

Ref document number: 2203757

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/003113

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1019970702786

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1995941340

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995941340

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970702786

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1995941340

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019970702786

Country of ref document: KR